natgillin/translations-raw huggingface dataset:
Clopidogrel Acino er et "generisk lægemiddel".
Clopidogrel Acino is a ‘generic medicine’.
Clopidogrel Acino indeholder hydrogeneret ricinusolie
Clopidogrel Acino contains hydrogenated castor oil
Clopidogrel Acino kan tages med eller uden mad.
Clopidogrel Acino may be taken with or without food.
Clopidogrel Acino Pharma 75 mg filmovertrukne tabletter
Clopidogrel Acino Pharma 75 mg film-coated tablets
Clopidogrel Acino Pharma er et ‘generisk lægemiddel’.
Clopidogrel Acino Pharma is a ‘generic medicine’.
Clopidogrel Acino Pharma GmbH 75 mg filmovertrukne tabletter
Clopidogrel Acino Pharma GmbH 75 mg film-coated tablets
Clopidogrel Acino Pharma GmbH er identisk med et referencelægemiddel, der allerede er godkendt i Den Europæiske Union (EU), og som hedder Plavix.
This means that Clopidogrel Acino Pharma GmbH is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Plavix.
Clopidogrel Acino Pharma GmbH kan gives til følgende patientgrupper: patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel Acino Pharma GmbH can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel Acino Pharma GmbH kan tages med eller uden mad.
Clopidogrel Acino Pharma GmbH may be taken with or without food.
Clopidogrel Acino Pharma GmbH må ikke gives til børn og unge.
Clopidogrel Acino Pharma GmbH is not intended for use in children or adolescents.
Clopidogrel Acino Pharma kan gives til følgende patientgrupper: patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel Acino Pharma can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel Acino Pharma kan tages med eller uden mad.
Clopidogrel Acino Pharma may be taken with or without food.
Clopidogrel Acino Pharma må ikke gives til børn og unge.
Clopidogrel Acino Pharma is not intended for use in children or adolescents.
Clopidogrel Apotex 75 mg filmovertrukne tabletter
Clopidogrel Apotex 75 mg film-coated tablets
Clopidogrel Apotex er et ‘generisk lægemiddel’.
Clopidogrel Apotex is a ‘generic medicine’.
Clopidogrel Apotex kan tages med eller uden mad.
Clopidogrel Apotex may be taken with or without food.
Clopidogrel BGR 75 mg filmovertrukne tabletter
Clopidogrel BGR 75 mg film-coated tablets Clopidogrel
Clopidogrel BGR 75 mg filmovertrukne tabletter clopidogrel
Clopidogrel BGR 75 mg film-coated tablets Clopidogrel
Clopidogrel BGR er et »generisk lægemiddel«.
Clopidogrel BGR is a ‘generic medicine’.
Clopidogrel BGR indeholder hydrogeneret ricinusolie
Clopidogrel BGR contains hydrogenated castor oil
Clopidogrel BGR indeholder hydrogeneret ricinusolie, der kan give maveproblemer og diarré.
Clopidogrel BGR contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel BGR indeholder lactose.
Clopidogrel BGR contains lactose
Clopidogrel BGR kan gives til følgende patientgrupper: patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel BGR can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel bleek geen effect te hebben op de vruchtbaarheid van mannelijke en vrouwelijke ratten en was niet teratogeen bij de rat of bij het konijn.
Clopidogrel was found to have no effect on the fertility of male and female rats and was not teratogenic in either rats or rabbits.
Clopidogrel BMS 300 mg filmovertrukkene tabletter clopidogrel
Clopidogrel BMS 300 mg film-coated tablets clopidogrel
Clopidogrel BMS 300 mg filmovertrukne tabletter
Clopidogrel BMS 300 mg film-coated tablets
Clopidogrel BMS 300 mg filmovertrukne tabletter clopidogrel
Clopidogrel BMS 300 mg film-coated tablets clopidogrel
Clopidogrel BMS 300 mg filmovertrukne tabletter er aflange, lyserøde, og er præget på den ene side med tallet ’300’ og på den anden side med tallet "1332".
Clopidogrel BMS 300-mg film-coated tablets are oblong, pink, engraved on one side with the number ‘300’ and on the other side with the number ‘1332’.
Clopidogrel BMS 75 mg filmovertrukket tablet clopidogrel
Clopidogrel BMS 75 mg film-coated tablets clopidogrel
Clopidogrel BMS 75 mg filmovertrukne tabletter
Clopidogrel BMS 75 mg film-coated tablets
Clopidogrel BMS 75 mg filmovertrukne tabletter er runde, bikonvekse, lyserøde, og er præget på den ene side med tallet "75" og på den anden side med tallet "1171".
Clopidogrel BMS 75-mg film-coated tablets are round, biconvex, pink, engraved on one side with the number ‘75’ and on the other side with the number ‘1171’.
Clopidogrel BMS indeholder laktose.
Clopidogrel BMS contains lactose.
Clopidogrel BMS kan anvendes til patienter, som har hjertetilfælde med ”forhøjelse af ST-segmentet” (ST-elevation) (dvs. en unormal visning på elektrokardiogrammet (EKG)), når lægen vurderer, at patienterne kan have gavn af denne behandling.
Clopidogrel BMS can be used in patients who are having a heart attack with an ‘ST segment elevation’ (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment.
Clopidogrel BMS kan gives til følgende patientgrupper: patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel BMS can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel BMS kan tages med eller uden mad.
Clopidogrel BMS may be taken with or without food.
Clopidogrel BMS må normalt ikke bruges samtidigt med medicin, der tages gennem munden, og som modvirker blodets størkning (orale antikoagulantia)
The use of oral anticoagulants (medicines used to reduce blood clotting) with Clopidogrel BMS is not recommended.
Clopidogrel BMS må normalt ikke bruges samtidigt med medicin, der tages gennem munden, og som modvirker blodets størkning (orale antikoagulantia).
The use of oral anticoagulants (medicines used to reduce blood clotting) with Clopidogrel BMS is not recommended.
Clopidogrel BMS tages for at forebygge dannelse af blodpropper (trombi) i blodårer (arterier), som er blevet stive ved en proces kaldet aterotrombose, hvilket kan føre til f.eks. slagtilfælde, hjerteanfald og død (aterotrombotiske hændelser).
Clopidogrel BMS is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Clopidogrel BMS tages for at forebygge dannelse af blodpropper (trombi), i blodårer (arterier) som er blevet stive, ved en proces kaldet aterotrombose, hvilket kan føre til slagtilfælde, hjerteanfald og død (aterotrombotiske hændelser).
Clopidogrel BMS is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Clopidogrel BMS tilhører en gruppe medicin, der kaldes blodforyndende medicin.
Clopidogrel BMS belongs to a group of medicines called antiplatelet medicinal products.
Clopidogrel bør gives som en enkelt daglig dosis på 75 mg med eller uden fødeindtagelse.
Clopidogrel should be given as a single daily dose of 75 mg.
Clopidogrel bør ikke anvendes til børn på grund af problemstillinger vedrørende virkning (se pkt.
Clopidogrel should not be used in children because of efficacy concerns (see section 5.1).
Clopidogrel bør ikke bruges til børn på grund af usikkerhed om virkningen (se pkt.
Clopidogrel should not be used in children because of efficacy concerns (see section 5.1)
Clopidogrel bør ikke bruges til børn på grund af usikkerhed om virkningen (se pkt.
Clopidogrel should not be used in children because of efficacy concerns (see section 5.1).
Clopidogrel dient bij deze patiënten derhalve met voorzichtigheid te worden gebruikt (zie rubriek 4.2).
Clopidogrel should therefore be used with caution in this population (see section 4.2).
Clopidogrel dient bij deze patiënten derhalve met voorzichtigheid te worden gebruikt (zie rubriek 4.2).
Therefore clopidogrel should be used with caution in these patients (see section 4.2).
Clopidogrel dient in een eenmaal daagse dosis van 75 mg te worden gegeven.
Clopidogrel should be given as a single daily dose of 75 mg.
Clopidogrel dura 75 mg filmovertrukne tabletter
Clopidogrel dura 75 mg film-coated tablets
Clopidogrel DURA er et ‘generisk lægemiddel’.
Clopidogrel DURA is a ‘generic medicine’.
Clopidogrel dura indeholder hydrogeneret ricinusolie
Clopidogrel dura contains hydrogenated castor oil
Clopidogrel dura indeholder hydrogeneret ricinusolie, der kan give maveproblemer og diarré.
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel DURA kan gives til følgende patientgrupper: patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel DURA can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel en ASA werden echter samen toegediend gedurende een periode tot één jaar (zie rubriek 5.1).
However, clopidogrel and ASA have been administered together for up to one year (see section 5.1).
Clopidogrel en de voornaamste circulerende (inactieve) metaboliet gaan in vitro een reversibele binding aan met humane plasma-eiwitten (respectievelijk 98% en 94%).
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively).
Clopidogrel er blevet evalueret sikkerhedsmæssigt hos mere end 42.000 patienter, der har deltaget i kliniske studier, inklusive over 30.000 patienter behandlet med clopidogrel plus ASA og over
Clopidogrel has been evaluated for safety in more than 42,000 patients who have participated in clinical studies, including over 30,000 patients treated with clopidogrel plus ASA, and over
Clopidogrel er blevet evalueret sikkerhedsmæssigt hos mere end 42.000 patienter, der har deltaget i kliniske studier, inklusive over 9.000 patienter der blev behanldet i mindst 1 år.
Clopidogrel has been evaluated for safety in more than 42,000 patients who have participated in clinical studies, including over 9,000 patients treated for 1 year or more.
Clopidogrel er blevet evalueret sikkerhedsmæssigt hos mere end 44.000 patienter, der har deltaget i kliniske studier, inklusive over 12.000 patienter der blev behandlet i mindst 1 år.
Clopidogrel has been evaluated for safety in more than 44,000 patients who have participated in clinical studies, including over 12,000 patients treated for 1 year or more.
Clopidogrel er blevet evalueret sikkerhedsmæssigt hos mere end 44.000 patienter, der har deltaget i kliniske studier, inklusive over 12.000 patienter der blev behanldet i mindst 1 år.
Clopidogrel has been evaluated for safety in more than 44,000 patients who have participated in clinical studies, including over 12,000 patients treated for 1 year or more.
Clopidogrel er blevet evalueret sikkerhedsmæssigt hos mere end 44.000 patienter, der har deltaget i kliniske studier, inklusive over 12.000 patienter, der blev behandlet i mindst 1 år. .
Clopidogrel has been evaluated for safety in more than 44,000 patients who have participated in clinical studies, including over 12,000 patients treated for 1 year or more.
Clopidogrel er indiceret hos :
Clopidogrel is indicated in:
Clopidogrel HCS 75 mg filmovertrukne tabletter clopidogrel
Clopidogrel HCS 75 mg film-coated tablets clopidogrel
Clopidogrel HCS er et "generisk lægemiddel".
Clopidogrel HCS is a ‘generic medicine’.
Clopidogrel HCS kan anvendes til patienter, som har hjertetilfælde med "forhøjelse af ST- segmentet" (ST-elevation) (dvs. en unormal visning på elektrokardiogrammet (EKG)), når lægen vurderer, at patienterne kan have gavn af denne behandling.
Clopidogrel HCS can be used in patients who are having a heart attack with ‘ST segment elevation’ (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment.
Clopidogrel HCS kan gives til følgende patientgrupper: patienter, som for nylig har haft myokardieinfarkt (hjerteanfald).
Clopidogrel HCS can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel heeft geen of verwaarloosbare invloed op de rijvaardigheid en op het vermogen om machines te bedienen.
Clopidogrel has no or negligible influence on the ability to drive and use machines.
Clopidogrel HEXAL 75 mg filmovertrukne tabletter
Clopidogrel HEXAL 75 mg film-coated tablets
Clopidogrel HEXAL 75 mg filmovertrukne tabletter Clopidogrel
Clopidogre HEXAL 75 mg film-coated tablets Clopidogrel
Clopidogrel HEXAL indeholder hydrogeneret ricinusolie, der kan forårsage mavetilfælde eller diarré
Clopidogrel HEXAL contains hydrogenated castor oil which may cause stomach upset or diarrhoea.
Clopidogrel HEXAL indeholder hydrogeneret ricinusolie, hvilket kan forårsage maveproblemer og diarré.
Clopidogrel HEXAL contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel Hexal kan anvendes til patienter, som har myokardieinfarkt med ”forhøjelse af ST-segmentet” (ST- elevation), dvs. en unormal visning på elektrokardiogrammet (EKG), når lægen vurderer, at patienterne kan have gavn af denne behandling.
Clopidogrel Hexal can be used in patients who are having myocardial infarction with ‘ST segment elevation’ (an abnormal reading on the electrocardiogram or ECG) when the doctor thinks that they would benefit from the treatment.
Clopidogrel Hexal kan gives til følgende patientgrupper: patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel Hexal can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel HEXAL kan tages med eller uden mad.
Clopidogrel HEXAL may be taken with or without food.
Clopidogrel HEXAL må ikke gives til børn og unge.
Clopidogrel HEXAL is not intended for use in children or adolescents.
Clopidogrel is een prodrug, een geneesmiddel waarvan één van de metabolieten een bloedplaatjesaggregatieremmer is.
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation.
Clopidogrel is getest in een reeks in vitro en in vivo genotoxiciteitsstudies, waarbij geen genotoxische activiteit werd vastgesteld.
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity.
Clopidogrel is geïndiceerd bij:
Clopidogrel is indicated in:
Clopidogrel Krka 75 mg filmovertrukne tabletter clopidogrel
Clopidogrel Krka 75 mg film-coated tablets Clopidogrel
Clopidogrel Krka anvendes til forebyggelse af aterotrombotiske hændelser hos voksne (problemer forårsaget af blodpropper og åreforkalkning).
Clopidogrel Krka is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Clopidogrel Krka d.d. indeholder clopidogrel og tilhører en lægemiddelgruppe, der kaldes blodfortyndende medicin.
Clopidogrel Krka d.d. contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products.
Clopidogrel Krka d.d. indeholder hydrogeneret ricinusolie
Clopidogrel Krka d.d. contains hydrogenated castor oil
Clopidogrel Krka d.d. indeholder hydrogeneret ricinusolie, der kan give maveproblemer og diarré.
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel Krka d.d. tages af voksne for at forebygge dannelse af blodpropper (trombi) i blodårer (arterier), som er blevet stive ved en proces kaldet aterotrombose, hvilket kan føre til f.eks. apopleksi, hjerteanfald og død (aterotrombotiske hændelser).
Clopidogrel Krka d.d. is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Clopidogrel Krka er et lægemiddel, der indeholder det aktive stof clopidogrel.
Clopidogrel Krka is a medicine that contains the active substance clopidogrel.
Clopidogrel Krka er et ‘generisk lægemiddel’.
Clopidogrel Krka is a ‘generic medicine’.
Clopidogrel Krka indeholder hydrogeneret ricinusolie
Clopidogrel Krka contains hydrogenated castor oil
Clopidogrel Krka indeholder hydrogeneret ricinusolie, der kan give maveproblemer og diarré.
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel Krka kan gives til følgende patientgrupper: patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel Krka can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel mag niet worden gebruikt bij kinderen vanwege werkzaamheidsbezwaren (zie rubriek 5.1).
Clopidogrel should not be used in children because of efficacy concerns (see section 5.1).
Clopidogrel metaboliseres først til en 2-oxo-clopidogrel-metabolit, der derefter metaboliseres til den aktive metabolit, et tiolderivat af clopidogrel.
Clopidogrel is first metabolised to a 2-oxo-clopidogrel intermediate metabolite.
Clopidogrel moet door CYP450-enzymen gemetaboliseerd worden om de actieve metaboliet te vormen die de bloedplaatjesaggregatie remt.
Clopidogrel must be metabolised by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation.
Clopidogrel Mylan 75 mg filmovertrukne tabletter
Clopidogrel Mylan 75 mg film-coated tablets
Clopidogrel Mylan er et ‘generisk lægemiddel’.
Clopidogrel Mylan is a ‘generic medicine’.
Clopidogrel Mylan indeholder hydrogeneret ricinusolie
Clopidogrel Mylan contains hydrogenated castor oil
Clopidogrel Mylan indeholder hydrogeneret ricinusolie, der kan give maveproblemer og diarré.
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel Mylan kan gives til følgende patientgrupper: patienter, som for nyligt har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel Mylan can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel og den cirkulerende (inaktive) hovedmetabolit binder reversibelt in vitro til humane plasma- proteiner (henholdsvis 98 % og 94 %).
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively).
Clopidogrel påvirker ikke eller i ubetydelig grad evnen til at føre bil eller betjene maskiner.
Clopidogrel has no or negligible influence on the ability to drive and use machines.
Clopidogrel påvirker ikke, eller i kun ubetydelig grad, evnen til at føre motorkøretøj eller betjene maskiner.
Clopidogrel has no or negligible influence on the ability to drive and use machines.
Clopidogrel Qualimed 75 mg filmovertrukne tabletter
Clopidogrel Qualimed 75 mg film-coated tablets
Clopidogrel Qualimed er et ‘generisk lægemiddel’.
Clopidogrel Qualimed is a ‘generic medicine’.
Clopidogrel Qualimed indeholder hydrogeneret ricinusolie, der kan give maveproblemer og diarré.
This medicinal product contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel Qualimed kan gives til følgende patientgrupper: patienter, som for nyligt har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel Qualimed can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel Qualimed kan tages sammen med eller uden mad.
Clopidogrel Qualimed may be taken with or without food.
Clopidogrel Qualimed tages for at forebygge dannelse af blodpropper (tromber) i blodårer (arterier), som er blevet stive ved en proces kaldet aterotrombose, hvilket kan føre til f.eks. apopleksi, hjerteanfald og død (aterotrombotiske hændelser).
Clopidogrel Qualimed is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Clopidogrel Qualimed tilhører en gruppe medicin, der kaldes blodfortyndende medicin.
Clopidogrel Qualimed belongs to a group of medicines called antiplatelet medicinal products.
Clopidogrel ratiopharm 75 mg filmovertrukne tabletter
Clopidogrel ratiopharm 75 mg film-coated tablets
Clopidogrel ratiopharm 75 mg filmovertrukne tabletter clopidogrel
Clopidogrel ratiopharm 75 mg film-coated tablets clopidogrel
Clopidogrel ratiopharm 75 mg filmovertrukne tabletter clopidogrel oral anvendelse.
Clopidogrel ratiopharm 75 mg film-coated tablets clopidogrel oral use
Clopidogrel ratiopharm 75 mg filmovertrukne tabletter er hvide til råhvide, marmorerede, runde og bikonvekse.
Clopidogrel ratiopharm 75 mg film-coated tablets are white to off-white, marbled, round and biconvex.
Clopidogrel ratiopharm er blodfortyndende medicin, der anvendes hos voksne til at forebygge problemer, som skyldes blodpropper og stivhed af arterierne (aterotrombotiske hændelser).
Clopidogrel ratiopharm is a blood-thinning medicine used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Clopidogrel ratiopharm er et ‘generisk lægemiddel’.
Clopidogrel ratiopharm is a ‘generic medicine’.
Clopidogrel ratiopharm er et “generisk lægemiddel”.
Clopidogrel ratiopharm is a ‘generic medicine’.
Clopidogrel ratiopharm GmbH 75 mg filmovertrukne tabletter Clopidogrel
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets Clopidogrel
Clopidogrel ratiopharm GmbH er et ‘generisk lægemiddel’.
Clopidogrel ratiopharm GmbH is a ‘generic medicine’.
Clopidogrel ratiopharm GmbH indeholder hydrogeneret ricinusolie, hvilket kan forårsage maveproblemer og diarré.
Clopidogrel ratiopharm GmbH contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel Ratiopharm GmbH kan anvendes til patienter, som har myokardieinfarkt med ”forhøjelse af ST- segmentet” (ST-elevation), dvs. en unormal visning på elektrokardiogrammet (EKG), når lægen vurderer, at patienterne kan have gavn af denne behandling.
Clopidogrel ratiopharm GmbH can be used in patients who are having myocardial infarction with ‘ST segment elevation’ (an abnormal reading on the electrocardiogram or ECG) when the doctor thinks that they would benefit from the treatment.
Clopidogrel Ratiopharm GmbH kan gives til følgende patientgrupper: patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel ratiopharm GmbH can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel ratiopharm indeholder det aktive stof clopidogrel.
Clopidogrel ratiopharm contains the active substance clopidogrel.
Clopidogrel ratiopharm indeholder hydrogeneret ricinusolie
Clopidogrel ratiopharm contains hydrogenated castor oil
Clopidogrel ratiopharm indeholder hydrogeneret ricinusolie, hvilket kan forårsage maveproblemer og diarré.
Clopidogrel ratiopharm contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Clopidogrel ratiopharm indeholder lactose
Clopidogrel ratiopharm contains lactose
Clopidogrel ratiopharm indeholder lactose.
Clopidogrel ratiopharm contains lactose.
Clopidogrel ratiopharm kan anvendes hos følgende grupper af patienter: patienter, der for nylig har haft et hjerteanfald (myokardieinfarkt).
Clopidogrel ratiopharm can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).
Clopidogrel ratiopharm kan anvendes hos patienter, der har et hjerteanfald med en bestemt unormalitet i elektrokardiogrammet (“ST-elevation”), når lægen mener, at de kan have fordel af behandlingen.
Clopidogrel ratiopharm can be used in patients who are having a heart attack with ‘ST segment elevation’ (an abnormal reading on the ECG or electrocardiogram) when the doctor thinks that they would benefit from the treatment.
Clopidogrel ratiopharm kan gives til følgende patientgrupper: patienter, som for nylig har haft et myokardieinfarkt (hjertetilfælde).
Clopidogrel ratiopharm can be given to the following groups of patients: patients who have recently had a myocardial infarction (heart attack).